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Objectives: To evaluate the effect of beclomethasone/formoterol versus budesonide/formo-
terol (non-inferiority) and versus formoterol (superiority) in patients with severe stable chronic
obstructive pulmonary disease (COPD).
Methods: A double-blind, double-dummy, randomised, active-controlled, parallel-group study.
After 4 weeks run-in with ipratropium/salbutamol (40/200 mg, three times daily) patients were
randomised to receive beclomethasone/formoterol (200/12 mg pressurised metered dose
inhaler), budesonide/formoterol (400/12 mg dry powder inhaler) or formoterol (12 mg dry
powder inhaler) twice daily for 48 weeks. Co-primary efficacy variables were change from
baseline to 48 weeks in pre-dose morning forced expiratory volume in 1 s (FEV1) and mean rate
of COPD exacerbations.
Results: Of 718 patients randomised, 703 (232 beclomethasone/formoterol, 238 budesonide/
formoterol, 233 formoterol) were in the ITT analysis. Improvement in pre-dose morning FEV1
was 0.077 L, 0.080 L and 0.026 L for beclomethasone/formoterol, budesonide/formoterol
and formoterol respectively (LS mean from the ANCOVA model). Beclomethasone/formoterol
was not inferior to budesonide/formoterol (95% CI of the difference 0.052, 0.048) and supe-
rior to formoterol (p Z 0.046). The overall rate of COPD exacerbations/patient/year was
similar and not statistically significantly different among treatments (beclomethasone/formo-
terol 0.414, budesonide/formoterol 0.423 and formoterol 0.431). Quality of life and COPD151 529 5886; fax: þ44 0 151 529 5888.
ac.uk (P.M.A. Calverley).
0 Published by Elsevier Ltd.
Beclomethasone/formoterol in COPD 1859symptoms improved in all groups and use of rescue medication decreased. Safety profiles were
as expected and treatments well-tolerated.
Conclusions: Beclomethasone/formoterol (400/24 mg) treatment for 48 weeks improved
pulmonary function, reduced symptoms compared to formoterol, was safe and well-tolerated
in patients with severe stable COPD. Neither of the long-acting b2-agonist/inhaled corticoste-
roid combinations affected the low exacerbation rate seen in this population.
ª 2010 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) remains
a highly prevalent condition,1 associated with episodic
exacerbations that impair health status.2 Based on exten-
sive clinical trials data treatment guidelines recommend
that a combination of a long-acting b-agonist (LABA) and an
inhaled corticosteroid (ICS) should be used to improve
symptoms and prevent exacerbations.3 This treatment is
usually confined to patients with spirometrically severe
disease (defined as forced expiratory volume in 1 s (FEV1)
<50% predicted), although recent data suggest benefit in
Global initiative in chronic Obstructive Lung Disease (GOLD)
stage II patients.4 There is both a molecular and clinical
rationale for combining LABAs and ICSs; LABAs increase
nuclear uptake of the glucocorticoid receptor/ligand
complex in vitro and corticosteroids up-regulate b-receptor
numbers in the cell membrane processes.5e7 This may
explain the greater improvement in lung function seen
when these drugs are combined compared with that
observed when LABAs or ICSs are used alone.8
To date most studies in COPD patients have investigated
combinations involving either fluticasone propionate or
budesonide. Beclomethasone dipropionate (BDP) is a widely
used ICS which has recently been combined with a LABA in
a single inhaler. BDP (100 mg) plus formoterol fumarate
(6 mg) is a fixed ICS/LABA combination delivered via
a pressurised metered dose inhaler (pMDI) using a hydro-
fluoralkane propellant. This has been formulated with an
extra-fine particle size which results in high lung deposition
with less amount of drug deposited in the upper airways.9,10
The BDP component in the extra-fine formulation of
beclomethasone/formoterol was able to achieve greater
efficacy per mg of delivered steroid compared to conven-
tional BDP.9 Therefore, the nominal dose of BDP per actu-
ation from beclomethasone/formoterol in the extra-fine
formulation is reduced from 250 mg (as in the conventional
BDP formulation) to 100 mg per actuation, thus lowering the
amount of inhaled ICS absorbed into the systemic circula-
tion.9 This improved delivery of beclomethasone/for-
moterol extra-fine formulation has the potential to target
inflammation and bronchoconstriction in the entire bron-
chial tree, including the smaller airways which is an
anatomical site particularly involved in the progression of
COPD.11e13 Moreover, the lung deposition pattern with
extra-fine beclomethasone/formoterol in COPD patients
was shown to be similar to that in asthmatics and normal
subjects.12
Beclomethasone/formoterol has been shown to be effec-
tive and well-tolerated in asthmatic patients. Comparative
clinical studies inmoderate-to-severe asthmatics have shown
that the efficacy of beclomethasone/formoterol is at leastcomparable to that of other ICS/LABA combinations across
a number of different asthma outcomes.14,15
The objective of this study was to investigate the efficacy
and safety of the fixed combination of beclomethasone/
formoterol (Foster, Chiesi Farmaceutici) in COPD patients,
and to compare it with the reference fixed combination of
budesonide/formoterol (Symbicort, AstraZeneca) and for-
moterol alone (Oxis, AstraZeneca) The hypotheses that
beclomethasone/formoterol was non-inferior to budeso-
nide/formoterol in terms of the change in pre-dose morning
FEV1 from baseline to 48 weeks and that beclomethasone/
formoterol was superior to formoterol alone in terms of the
mean rate of COPD exacerbations per patient per year were
tested.
Methods
Patients
Hospital outpatients with severe stable COPD according to
the GOLD guidelines were recruited. Patients were required
to be aged 40 years with a diagnosis of symptomatic COPD
for >2 years, at least a 20 pack-years smoking history,
a post-bronchodilator FEV1 between 30% and 50% of the
predicted normal and at least 0.7 L absolute value and
a pre-dose FEV1/forced vital capacity (FVC) of 0.7.
Moreover, patients needed to have experienced at least
one exacerbation requiring medical intervention (oral
corticosteroid and/or antibiotic treatment and/or need for
a visit to an emergency department and/or hospitalisation)
within 2e12 months before the screening visit and to be
clinically stable for the 2 months before study entry.
Finally, a change in FEV1 <12% of predicted normal value
30 min following inhalation of 200 mg of salbutamol pMDI
was a prerequisite for inclusion. Patients were excluded if
they had a history of asthma, allergic rhinitis or other
atopic disease, variability of symptoms from day to day and
frequent symptoms at night and early morning (suggestive
of asthma). They were also excluded if they were receiving
long term oxygen therapy or they had a lower respiratory
tract infection or had been hospitalised for an acute COPD
exacerbation within two months before screening or during
the run-in period. Treatment with oral, injectable or depot
corticosteroids and antibiotics, long-acting antihistamines
or changes in the dose of an oral modified release
theophylline in the two months preceding screening and
during the run-in period were also exclusion criteria.
Study design
This was a 48-week, phase III, double-blind, double-
dummy, randomised, active-controlled, 3-arm parallel-
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NCT476099) conducted in 76 centres in 8 countries across
Europe. The study protocol was approved by the Institu-
tional Review Board/Independent Ethics Committee of
participating centres. The study was conducted in accor-
dance with Good Clinical Practice, the Declaration of
Helsinki and all applicable regulations. All patients gave
written informed consent prior to study entry.
During the 4-week run-in period all non-permitted
COPD treatments were discontinued and eligible patients
were treated with combination ipratropium/salbutamol
(20/100 mg, two inhalations three times daily). Rescue
salbutamol was permitted throughout the study as
required. This was the only treatment allowed in the 24 h
preceding the randomisation visit (Week 0) but its use was
avoided for 8 h before the visit. At Week 0, patients satis-
fying all the eligibility criteria were randomised in a 1:1:1
ratio to receive 48 weeks treatment with either: beclo-
methasone/formoterol pMDI 100/6 mg, two inhalations
twice daily (total daily dose 400/24 mg), budesonide/for-
moterol dry powder inhaler (DPI) 200/6 mg, two inhalations
twice daily (total daily dose 800/24 mg) or formoterol DPI
12 mg, one inhalation twice daily (total daily dose 24 mg).
The randomisation scheme followed a balanced-block
centre-stratified design and was prepared via a compu-
terised system. Patients were centrally assigned, in each
centre, to one of the three treatment arms at the end of
the run-in period through an Interactive Voice/Web
Response System (IXRS). Almac Clinical Technologies (UK)
was in charge of the IXRS study drug management. The
investigators at the sites called the IXRS to screen and
randomise patients. The IXRS assigned the patient to
a certain treatment group using a list-based randomisation
algorithm and assigned the medication kit number corre-
sponding to the treatment group. Study drug was kitted and
uniquely numbered and the IXRS was used to assign both
initial and subsequent kits in order to have an inventory
control and patient dose tracking. The IXRS also maintained
quantities, kit numbers, drug types, batch/code numbers,
expiration dates and did not dispense after these dates. On
each study day, patients took both active medications and
matched placebo twice daily, in order to maintain blinding.
In case of emergency, unblinding of the treatment code was
done through IXRS. Clinic visits took place at the start and
end of the run-in period, and at 4, 12, 24, 36 and 48 weeks
after randomisation at Week 0.
Assessments
The co-primary efficacy variables were the change in pre-
dose morning FEV1 from baseline to 48 weeks and the mean
rate of COPD exacerbations per patient per year. Pulmo-
nary function tests (FEV1, FVC, Peak expiratory flow [PEF]
and forced expiratory flow at 25e75% vital capacity
[FEF25e75%]) were measured according to the American
Thoracic Society/European Respiratory Society
recommendation.16
Lung function parameters were measured pre-dose
(time 0) at all visits, and 30, 60, 120 and 180 min post-
dosing at weeks 0, 4, 24 and 48.
COPD exacerbations were defined by the need for
treatment with oral corticosteroids and/or antibioticsand/or the need to visit or be admitted to a hospital.
Their occurrence was documented at all visits together
with dyspnoea scores (using the Modified Medical
Research Council questionnaire). At Weeks 0, 4 and 48,
after the pulmonary function tests and before adminis-
tration of study drug, health-related quality of life was
assessed using the St. George’s Respiratory Question-
naire (SGRQ). A 6-min walking test (6-MWT) was per-
formed according to standard methodologies17 and from
these data the Body Mass Index, airflow Obstruction,
Dyspnoea and Exercise capacity (BODE) index was
calculated.18 Throughout the study, the pulmonary
function assessments at the clinic visits started in the
morning between 8.00 and 10.00 a.m. at approximately
the same time for each patient. Patients recorded COPD
symptoms daily each morning using a diary card. The use
of study medication and rescue medication was also daily
recorded.
Safety evaluation
Evaluation of the safety profile included adverse events and
vital signs (heart rate and blood pressure) at every visit. A
12-lead electrocardiogram (ECG) was performed pre-dose
and after the 60 min post-dose pulmonary function tests at
Weeks 0, 24 and 48. ECG recordings were centralised for
evaluation (including evaluation of QTc interval which was
corrected using Bazett’s and Fridericia’s equations). Holter
monitoring was also conducted in a subgroup of 10% of
patients at baseline (week 0) and at week 48 and the 24-h
recording was also collected and shipped to the central
laboratory for evaluation. Blood samples for routine hae-
matology and biochemistry were taken at Weeks 0, 4 and
48. Serum cortisol was assessed pre-dose and serum
potassium and plasma glucose were assessed pre-dose and
after the 30 min post-dose pulmonary function tests at
Weeks 0, 24 and 48. An Independent Safety Monitoring
Committee was established in order to ensure an inde-
pendent scrutiny of the study and the ongoing safety of trial
subjects.
Sample size
The aim of the study was to show both non-inferiority of
beclomethasone/formoterol versus budesonide/formoterol
(in terms of change in pre-dose morning FEV1 from baseline
to 48 weeks) and superiority of beclomethasone/formoterol
versus formoterol (in terms of mean rate of COPD exacer-
bations per patient per year).
With a sample size of 192 patients per group, assuming
exacerbations were experienced by 50% of patients in the
beclomethasone/formoterol group and 66% in the for-
moterol group, the power for detecting a statistically
significant difference, using a Poisson regression (assuming
a homogeneous exponential distribution of exacerbations),
was estimated at 97%.
For the change in pre-dose morning FEV1 after 48 weeks
of treatment, this sample size had more than 80% power to
show non-inferiority of beclomethasone/formoterol versus
budesonide/formoterol (one-sided significance level set at
2.5%) assuming a standard deviation of 340 mL with a non-
inferiority margin of 100 mL. Therefore, assuming a 30%
Beclomethasone/formoterol in COPD 1861drop-out rate, a total of 275 patients per group were to be
randomised.
Statistical methods
Efficacy data were analysed for both the intention-to-treat
(ITT) population and the per-protocol (PP) population. The
ITT population included all randomised patients who
received at least one inhalation of study drug and had at
least one post-baseline efficacy evaluation. The PP pop-
ulation included all patients in the ITT analysis set who did
not have any major protocol violations. The safety pop-
ulation included all randomised patients who received at
least one inhalation of study medication. Missing values
were accounted for using the last observation carried
forward (LOCF) approach.
For the change in pre-dose morning FEV1 from baseline to
48 weeks, the non-inferiority of beclomethasone/for-
moterol versus budesonide/formoterol and its superiority
versus formoterol were tested using an analysis of covari-
ance (ANCOVA) model with treatment and centre as factors
and baseline FEV1 as covariate. The number of COPD exac-
erbations (mean rate per patient per year) was analysed
using Poisson regression with log-time on the study as an
offset. Standard errors were estimated allowing for extra-
Poisson variation. Superiority testing was conducted using
a two-sided significance level set at 5% (i.e. a Z 0.05).
Within treatment comparisons for exacerbation rates
before entering the study (as recorded within 2e12 months
before the screening visit) and during the study period,
were performed by using a generalised estimating equa-
tions (GEE) approach to Poisson regression accounting for
within-patient correlation. The analysis was performed
within each treatment group, separately.
All other pulmonary function tests and secondary effi-
cacy variables were analysed using an ANCOVA model with
treatment and centre as factors and baseline values as
covariate. Adverse events were coded by system organ
class (SOC) and preferred term (PT) using the MedDRA
dictionary and were compared using the Chi-square test or
Fisher’s exact test (the latter if at least one cell count was
less than five). Laboratory parameters, vital signs and ECG
QTc intervals were described using summary statistics and
relevant parameters were compared using the ANCOVA
model.
Results
Patients
Of the 828 patients screened, 718 patients were rando-
mised to receive treatment and 621 patients completed the
study (Fig. 1). Of these patients only 13 were older than 70
years and had an FEV1/FVC ratio >0.65 and so might not
have been classified as having COPD using the lower limit of
normal for this ratio. These patients were similarly
distributed between the groups, and their data are repor-
ted here on an intention-to-treat basis. The first patient
entered in December 2006, the last patient entered in July
2007 and the last patient’s last visit was in August 2008. The
most common causes of early study discontinuation werewithdrawn consent and adverse events. Consent with-
drawal was less frequent with combination treatment than
with formoterol (4.2%, 5.8% and 9.7%, in beclomethasone/
formoterol, budesonide/formoterol and formoterol groups,
respectively). Frequencies of withdrawals due to adverse
events were similar among the treatments and ranged from
2.1% to 3.8%.
At baseline, the three treatment groups were well-
matched in their demographic and functional characteris-
tics (Table 1). The mean FEV1 % predicted at study entry
ranged from 41.9% (beclomethasone/formoterol) to 42.5%
(formoterol).
Efficacy evaluation
Of the 237 randomised patients in the beclomethasone/
formoterol group, 232 and 223 were analysed in the ITT and
PP populations respectively and were analysed for the
primary outcome variables. The corresponding numbers for
the budesonide/formoterol and formoterol groups respec-
tively were 242 and 239 randomised, 238 and 233 in the ITT
population and 231 and 225 in the PP population.
Lung function
The change in pre-dose morning FEV1 during the study is
shown in Fig. 2. Although pre-dose morning FEV1 increased
from baseline in all treatment arms, this improvement
(calculated as LS mean from the ANCOVA model) was
significantly greater in the beclomethasone/formoterol and
budesonide/formoterol groups (0.077 L and 0.080 L
respectively) compared to the formoterol group (0.026 L).
Beclomethasone/formoterol was shown to be comparable
to budesonide/formoterol (difference 0.002 L; lower limit
of unilateral 97.5% CIZ 0.052) and superior to formoterol
(difference 0.051 L; 95% CI 0.001 to 0.102; p Z 0.046).
Similar results were obtained in the PP population.
The peak post-dose FEV1 was significantly greater with
beclomethasone/formoterol than with formoterol alone
(pZ 0.033) (Fig. 3), as was the post-dose 3 h average FEV1
(p Z 0.039) (Fig. 7 online repository). The improvement in
pre-dose FVC versus baseline was statistically significant
for beclomethasone/formoterol (p Z 0.005) but not for
budesonide/formoterol (pZ 0.152) or formoterol (pZ 0.582)
(Fig. 4). The results of the other pulmonary function param-
eters (FVC, PEF, FEF25e75%) showed no significant differences
between treatments in pre-dose values, peak values and 3 h
post-dose values (Table 3 online repository).
Exacerbations
The number of patients with at least one COPD exacerba-
tion and the mean rate of COPD exacerbations per patient
per year were similar and did not differ significantly
between treatments. In the beclomethasone/formoterol
group 64 (27.6%) patients experienced at least one exac-
erbation giving an exacerbation rate of 0.414 per patient
per year. Corresponding figures for budesonide/formoterol
were 64 (26.9%) patients with exacerbations giving a rate of
0.423 and for formoterol 66 (28.3%) patients giving a rate of
0.431 (Fig. 5). The number of patients with COPD exacer-
bations leading to hospitalisation was 13 (5.6%) for beclo-
methasone/formoterol, 7 (2.9%) for budesonide/formoterol
Figure 1 Consort Flow diagram. BDP/FF: beclomethasone/formoterol; BUD/FF: budesonide/formoterol; FF: formoterol;
AEsZ adverse events; PVZ protocol violations; LRZ lack of therapeutic response; PCZ poor compliance to study drug intake or
study procedure; CE Z COPD exacerbation; CW Z consent withdrawn; NM Z need of a non-permitted medication; LF Z lost to
follow-up; FO Z FEV1 outside the scheduled range; EO Z eosinophil count outside the scheduled range; OR Z other reasons.
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for formoterol (p Z 0.008 versus beclomethasone/for-
moterol). The mean rate per patient per year was 0.074 in
the beclomethasone/formoterol, 0.033 in the budesonide/
formoterol group and 0.040 in the formoterol group. The
rate ratio (95% CI) between the beclomethasone/for-
moterol and the other two groups was 2.222 (1.384e3.567)
versus the budesonide/formoterol group and 1.844
(1.173e2.901) versus the formoterol group.
The rate of hospitalisations in all the treatment groups
was lower compared to a previous COPD trial.8 Also,
differences between countries were observed in terms of
rates of exacerbations requiring hospitalisations. This
could reflect country-specific healthcare policies con-
cerning admission to hospital of exacerbated patients.
Therefore, a post-hoc analysis was carried-out in patients
with COPD exacerbations requiring oral corticosteroids
and/or antibiotic who were managed in a hospital setting
(either ER or unscheduled outpatient visit or hospital-
isation). This analysis showed that the mean rate per
patient per year was 0.162 in the beclomethasone/for-
moterol group, 0.180 in the budesonide/formoterol group
and 0.180 in the formoterol group. The comparison
between the groups showed that the rate of COPD exac-
erbations leading to ER/unscheduled visits/hospitalisation
in the beclomethasone/formoterol group was not statisti-
cally significantly different to that reported either in the
budesonide/formoterol group (p Z 0.597) or in the for-
moterol group (p Z 0.607).Other outcome measures
Dyspnoea score: The improvement (i.e. reduction) in
dyspnoea score compared to baseline was similar for
beclomethasone/formoterol (0.19  0.74) and budeso-
nide/formoterol (0.18  0.78) and was greater than that
observed for formoterol (0.07  0.76) (Fig. 8 online
repository). The within group improvement was statisti-
cally significant for both the combination groups
(p < 0.001) but not for the formoterol group. No statisti-
cally significant differences were found in the comparison
between treatments.
Six minute walking test
The distance covered in 6 min at Week 48 was significantly
greater versus baseline in all the three groups (p < 0.001),
and did not significantly differ between treatments. The
change in distance covered was higher, though not signifi-
cantly so, in the beclomethasone/formoterol group
(41  85 m) than in the budesonide/formoterol group
(35  86 m) or the formoterol group (35  79 m) (Fig. 6).
St. George’s Respiratory Questionnaire
The SGRQ mean total score decreased during the study
indicating an improved quality of life (Table 2). Changes
from baseline were statistically significant for all the three
treatments, with no significant differences between the
Table 1 Demographics and baseline characteristics (ITT population).
Characteristic Beclomethasone/formoterol
(N Z 232)
Budesonide/formoterol
(N Z 238)
Formoterol
(N Z 233)
Age (years) 63.0  9.0
(range 41e83)
64.1  9.1
(range 40e84)
63.7  8.8
(range 41e84)
Males (n, %) 184 (79.3%) 194 (81.5%) 189 (81.1%)
Duration of the disease (years) 9.41  7.0 9.89  7.8 9.83  6.7
No. exacerbations/patient
(2e12 months of screening)
1.73  1.0 1.67  1.0 1.79  1.0
Smoking habits
Smokers (n, %) 90 (38.8%) 86 (36.1%) 87 (37.3%)
Ex-smokers (n, %) 142 (61.2%) 152 (63.9%) 146 (62.7%)
Duration of smoking (years) 36.0  10.3 36.0  10.4 36.6  10.9
Number of pack/year 37.3  14.1 37.8  14.6 39.7  19.1
Previous Treatment (n, %)
LABA* 103 (44.4%) 100 (43.2%) 100 (42.92%)
Long-acting anticholinergic 17 (7.33%) 12 (5.04%) 16 (6.87%)
ICS* 101 (43.53%) 87 (36.55%) 84 (36.05%)
ICS/LABA fixed combination 15 (6.47%) 25 (10.5%) 13 (5.58%)
FEV1 (L) pre-bronchodilator 1.14  0.3 1.16  0.3 1.14  0.3
FEV1 % predicted normal
pre-bronchodilator
41.9  5.6 42.3  6.0 42.5  5.9
Reversibility test %
(change in FEV1 % predicted)
2.94  3.6 2.47  4.0 2.97  3.2
BODE index 3.99  1.5 3.97  1.5 4.00  1.5
SGRQ score 60.4  19.5 57.2  18.6 59.5  20.2
6 min walking test (metres) 334.7  116.7 333.9  119.1 332.0  121.9
All values are presented as absolute numbers or mean  standard deviation.
ITT: intention-to-treat; LABA: long-acting b2-agonist; ICS: inhaled corticosteroid; FEV1: forced expiratory volume in 1 s; BODE: Body mass
index, airflow Obstruction, Dyspnoea and Exercise capacity; SGRQ: St. George’s Respiratory Questionnaire.
* used alone or in combination.
Beclomethasone/formoterol in COPD 1863groups. The percentage of patients with a change from
baseline in the SGRQ 4 units increased over time in all the
groups (Fig. 9 online repository).
BODE index
A significant improvement in the BODE index was observed
during the study in all treatment groups (p < 0.001). TheFigure 2 Change in pre-dose FEV1 (from baseline to 48 weeks)
following 48 weeks treatment with beclomethasone dipropio-
nate/formoterol (BDP/FF), budesonide/formoterol (BUD/FF) or
formoterol (FF) in patients with severe stable COPD. FEV1:
forced expiratory volume in 1 s $ Non significant difference BDP/
FF versus BUD/FF (p Z 0.928); #p Z 0.046 BDP/FF versus FF;
*p < 0.001 for both combination treatments versus baseline.improvement (i.e. decrease) in the BODE index compared
to baseline was similar for beclomethasone/formoterol
(0.61  1.23) and budesonide/formoterol (0.64  1.36),
and was greater than that observed for formoterol
(0.44  1.26), although this difference was not statisti-
cally significant.Figure 3 Post-dose peak FEV1 following 48 weeks treatment
with beclomethasone dipropionate/formoterol (BDP/FF),
budesonide/formoterol (BUD/FF) or formoterol (FF) in patients
with severe stable COPD. FEV1: forced expiratory volume in 1 s
#p < 0.05 beclomethasone/formoterol versus formoterol;
*p < 0.05 versus baseline.
Figure 4 Change in pre-dose FVC (from baseline to 48 weeks)
following 48 weeks treatment with beclomethasone dipropio-
nate/formoterol (BDP/FF), budesonide/formoterol (BUD/FF)
or formoterol (FF) in patients with severe stable COPD. FVC:
forced vital capacity. *p Z 0.005 versus baseline.
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There were no statistically significant differences among
treatments regarding COPD symptom scores. In all groups
there was statistically significant improvement versus
baseline in breathlessness, and cough (Table 2). Statisti-
cally significant improvement versus baseline in breath-
lessness on rising and days without COPD symptoms was
observed with both the combination groups but not with
formoterol alone.
Use of rescue medication
The use of rescue salbutamol decreased in all treatment
groups during the study, but was more evident in the beclo-
methasone/formoterol and budesonide/formoterol groups
than in the formoterol group (Fig. 10 online repository),
although no statistically significant difference was observedFigure 5 Exacerbation rate (number per patient per year) at
baseline (dotted outline) and during (solid outline) the study
following 48 weeks treatment with beclomethasone dipropio-
nate/formoterol (BDP/FF), budesonide/formoterol (BUD/FF)
or formoterol (FF) in patients with severe stable COPD.
#p < 0.001 versus baseline.among treatments. The mean change from baseline in the %
of days without rescue was higher for beclomethasone/for-
moterol (7.90  34.89%) and budesonide/formoterol
(10.59  31.11%) than formoterol (0.85  33.46%). No
statistically significant difference was observed between
treatments.
Safety evaluation
The mean extent of exposure was similar in all treatment
groups and ranged between 304.99 days and 315.22 days.
The incidence of adverse events (AEs), serious AEs,
adverse drug reactions (ADRs) and withdrawals due to AEs
was not significantly different among the three treatment
groups (Table 4 online repository). The most commonly
reported AE was exacerbation or worsening of COPD
reported in 27e28% of patients. Pneumonia was reported
by 5 (2.1%) patients in the beclomethasone/formoterol
group, 7 (2.9%) in the budesonide/formoterol group and 1
(0.4%) in the formoterol group. A total of 20 patients
withdrew from the study due AEs: 9 (3.8%) in the beclo-
methasone/formoterol group, 6 (2.5%) in the budesonide/
formoterol group and 5 (2.1%) in the formoterol group.
Changes in vital signs, 12-lead ECG, QT interval and
Holter assessments were rare, and did not raise any unex-
pected safety concern regarding the known profile of ICSs
and LABAs in the treatment of COPD. Changes from baseline
in serum cortisol were not statistically significant in any
treatment group.
Six patients died during the treatment (two in the
beclomethasone/formoterol group and four in the budeso-
nide/formoterol group). None of deaths were considered to
be related to the study medication.
Discussion
Many studies have considered whether the treatment with
LABA/ICS is better than placebo or the individual treatment
components.19e21 A clear statement on this came from the
large TORCH study which demonstrated small but definite
superiority in terms of lower exacerbation numbers when
using combination treatment.8 That study was powered to
demonstrate a difference in mortality, so it was thus
significantly over-powered for an outcome of exacerbation.
By contrast, the present study using beclomethasone/for-
moterol included a more modest number of patients, but
should nonetheless have been sufficient to determine
whether treatments were effective. This proved to be the
case for one of the co-primary endpoints, pre-dose FEV1,
but not for the exacerbation rate. The reason this occurred
has implications for the interpretation of other studies and
future clinical trial design.
Spirometry in general, and specifically the FEV1, is
a robust assessment which is reproducible, is an accepted
key marker for disease progression22 and has the ability to
measure the different responses to interventions. These are
the reasons why it is supported by regulatory agencies as
a study endpoint. In the present study both combination
treatments showed significant and sustained increases from
baseline in FEV1 of similar magnitude, which were signifi-
cantly greater than that observed with formoterol alone.
Figure 6 Improvement in 6 min walking test (6-MWT) from
baseline to 4 and 48 weeks following treatment with beclo-
methasone dipropionate/formoterol (BDP/FF), budesonide/
formoterol (BUD/FF) or formoterol (FF) in patients with severe
stable COPD. *p<0.001 vs. baseline.
Beclomethasone/formoterol in COPD 1865This finding reflects the additional contribution of the
steroid component, and it can be linked to its anti-inflam-
matory effect. The extra-fine beclomethasone/formoterol
combination was not inferior to the combination of bude-
sonide/formoterol, despite the lower ICS dose included in
the combination (400 mg/daily versus 800 mg/daily, respec-
tively). The improvement from baseline observed with both
beclomethasone/fomoterol and budesonide/formoterol in
peak FEV1 was well above 200 mL (i.e. over the suggested
minimal important difference considered to be clinically
relevant23). These enhanced bronchodilatory responses
indicate an effective up-regulation of the b2 receptors in the
airways of COPD patients induced by the beclomethasoneTable 2 Mean changes in St. George’s Respiratory Questionnair
COPD symptom scores from baseline to 48 weeks (ITT population
Characteristic Beclomethasone/formoterol
(N Z 232)
SGRQ Total score
Baseline 50.89  15.35
4-week mean change 4.09  11.27*
48-week mean change 3.75  13.91*
Breathlessness
Baseline 1.11  0.71
Mean change 0.13  0.67*
Waking at night
Baseline 0.38  0.55
Mean change 0.04  0.54
Breathlessness on rising
Baseline 0.95  0.74
Mean change 0.10  0.64*
Cough
Baseline 1.01  0.65
Mean change 0.18  0.67*
% Days without COPD symptoms
Baseline 5.27  18.98
Mean change 3.17  23.80#
All values are presented as mean  standard deviation.
ITT: intention-to-treat; COPD: chronic obstructive pulmonary disease
Statistically significant versus baseline value: *p < 0.01, **p Z 0.03and budesonide components, respectively. Improvements in
FVC occurred in all the groups, although only in the BDP/
formoterol group did this achieve statistical significance. It
has been suggested that improvement in FVC may indicate
a reduction of air trapping associated with small airways
patency.11 For this reason the greater FVC improvement
observed with beclomethasone/formoterol is consistent
with a more efficient peripheral deposition in COPD patients
due to the extra-fine aerosol that characterises this formu-
lation and it is in line with the previous findings in
asthma.14,24,25
Unlike previous studies using the budesonide/formoterol
combination,19,20 the exacerbation rate did not differ
between treatment arms. This study was powered on the
basis of an earlier trial conducted by Calverley et al.20 some
years earlier. Nevertheless, the patients recruited in the
present study were more like those enrolled in the TRISTAN
study21 in terms of their baseline lung function and repor-
ted exacerbation frequency. However, the observed exac-
erbation rates at the end of this study were less than half
those reported in the TRISTAN study and many other tri-
als.26e28 This low number of exacerbations cannot be due to
different background therapy used before study entry,
which was indeed similar to that in other studies of LABA/
ICS combinations. The lower than expected exacerbation
rate may have been due to the requirement for patients to
be free from exacerbations for 2 months before study
entry. This inclusion criterion may have inadvertently
biased the recruitment of stable patients who were less
likely to exacerbate thereafter. Indeed, recent data have
shown exacerbations tend to cluster,29 so the patients
recruited in the present study may have been in a periode (SGRQ) total score from baseline to 4 and 48 weeks and in
).
Budesonide/formoterol
(N Z 238)
Formoterol
(N Z 233)
49.66  15.79 50.47  16.21
4.19  10.07* 2.72  10.73*
4.28  11.92* 2.90  13.28*
1.08  0.72 1.09  0.67
0.13  0.62* 0.09  0.65**
0.38  0.57 0.38  0.56
0.04  0.48 0.04  0.59
0.88  0.78 0.94  0.80
0.11  0.60*** 0.02  0.62
0.94  0.66 0.93  0.65
0.10  0.63**** 0.14  0.61*
7.11  20.89 8.37  23.24
3.15  24.13# 3.07  27.78
.
, ***p Z 0.023, ****p Z 0.021, #p Z 0.046.
1866 P.M.A. Calverley et al.when they were no longer prone to exacerbate. A second
consideration relates to the geographical distribution of
recruited patients. Patients may not have experienced an
exacerbation due to regular and close monitoring by the
treating physician as part of the study protocol (the so
called “clinical trial effect”). As most patients came from
Eastern Europe, this effect might have been particularly
relevant in some of these countries. Adherence to treat-
ment can have an important impact on exacerbations as
was seen in the TORCH study.30 This possibility should be
considered when planning future studies.
In this study, the rates of COPD exacerbations leading to
hospitalisation were very low compared to a previous trial.8
Indeed, the rate of hospitalisations in patients treated with
beclomethasone/formoterol combination was less than half
the value observed in the TORCH trial in subjects receiving
fluticasone/salmeterol combination. Again, there were
large inter-countries differences in the rates of hospital-
isation reported during the study. Although reliance on
hospitalisation could work well in identifying severe exac-
erbations in a single country, it does not necessarily reflect
what happens in different healthcare systems where
hospital accessibility can differ. Therefore, under the
assumption that the more severe episodes require
a hospital-based assessment (either ER or unscheduled
outpatient visit or hospitalisation), we performed a post-
hoc analysis comparing COPD exacerbations that were
managed in a hospital setting, and that required systemic
corticosteroids and/or antibiotic treatment and, accord-
ingly, to be considered as severe. No difference between
the three study treatments was observed. Interestingly,
when measured in this way, the annual rates of severe
exacerbations per patient/year ranged from 0.16 to 0.18
among groups, a value which is similar to that reported in
the TORCH trial.8
Improvements in symptoms and patient reported
outcomes were also observed during the study. The
improvements in the dyspnoea score, COPD symptoms
scores and BODE index were more marked with both ICS/
LABA combinations compared with LABA alone, which is
consistent with previous studies.19,20 There were significant
improvements in the SGRQ scores which exceeded the
clinically important difference of four units at four weeks
of treatment, and remained close to this level over the
subsequent 44 weeks. At the end of the study the change in
the distance covered in the 6-min walking test was highest,
although not statistically significant, in the patients
receiving beclomethasone/formoterol followed by budeso-
nide/formoterol and then formoterol alone. On average,
the improvement with beclomethasone/formoterol in the
6-min walking test was above the threshold of 37 m, which
has been recently described as clinically relevant.23 This
ability to walk further after treatment with beclometha-
sone/formoterol may be linked to the improvement in air
trapping experienced by the patients.31
No unexpected or unusual safety signals of clinical
concern were observed in this one year trial. In the three
arms no cardiac safety concerns were raised by ECG and
Holter evaluations. In addition there was a low dropout
rate, but the study was not powered to completely exclude
any very rare adverse event. The rate of reported pneu-
monia was similar to that reported in placebo-controlledtrials using budesonide, where no pneumonia signals of
concern have been observed over 1 year treatment.32
In summary, the fixed combination of beclomethasone/
formoterol (total daily dose 400/24 mg) given for 48 weeks
in patients with severe COPD improved pulmonary function
and lessened disability. The increase in pre-dose FEV1 with
beclomethasone/formoterol, administered at a nominal
dose of BDP two-fold lower than the equipotent daily dose
of budesonide, was comparable to budesonide/formoterol
(total daily dose 800/24 mg) and superior to formoterol
alone (total daily dose 24 mg).
No difference was observed between treatments
regarding the low exacerbation rate seen in this patient
population. The use of beclomethasone/formoterol
improved health-related quality of life, reduced rescue
medication use and was safe and well-tolerated.Acknowledgements
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